Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBUZWQ)

• Drug Name: 3alpha-(bis-chloro-phenylmethoxy)tropane Drug Info
• Synonyms: CHEMBL119664; CHEMBL541825; SCHEMBL1152029; BDBM50039177; 3-[Bis(4-chlorophenyl)methoxy]tropane; 3-[Bis-(4-chloro-phenyl)-methoxy]-8-methyl-8-aza-bicyclo[3.2.1]octane

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 10068100
  TTD Drug ID: DMBUZWQ

Molecule-Related Drug Atlas

Drug(s) Targeting Norepinephrine transporter (NET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[2]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[3]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[4]
Desipramine	DMT2FDC	Attention deficit hyperactivity disorder	6A05.Z	Approved	[2]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[5]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[6]
Tapentadol hydrochloride	DMXLSH3	Acute pain	MG31	Approved	[7]
Venlafaxine	DMR6QH0	Anxiety disorder	6B00-6B0Z	Approved	[6]
Trimipramine	DM1SC8M	Major depressive disorder	6A70.3	Approved	[8]
Duloxetine	DM9BI7M	Depression	6A70-6A7Z	Approved	[9]

Drug(s) Targeting Serotonin transporter (SERT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[2]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[3]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[10]
Vortioxetine	DM6F1PU	Major depressive disorder	6A70.3	Approved	[11]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[12]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[5]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[6]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[10]
Nortriptyline	DM4KDYJ	Depression	6A70-6A7Z	Approved	[10]
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[10]

Drug(s) Targeting Muscarinic acetylcholine receptor M1 (CHRM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ACECLIDINE	DMOLNCZ	Glaucoma/ocular hypertension	9C61	Approved	[13]
Fesoterodine fumarate	DM13495	Overactive bladder	GC50.0	Approved	[14]
SMT-D002	DM1I93C	Seborrhea	ED91.2	Approved	[15]
Clidinium	DMUMQZ0	Abdominal stomach pain	DD91.4	Approved	[16]
Trihexyphenidyl	DMB19L8	Dystonia	8A02	Approved	[17]
Oxyphenonium	DMMQHOZ	Visceral spasms	MD81.4	Approved	[18]
Benztropine	DMGZOVN	Parkinson disease	8A00.0	Approved	[19]
Glycopyrrolate	DM2M3ZA	Anaesthesia	9A78.6	Approved	[20]
Pirenzepine	DMP6M1N	Peptic ulcer	DA61	Approved	[21]
Cycrimine	DM8C43Q	Parkinson disease	8A00.0	Approved	[22]

Drug(s) Targeting Dopamine transporter (DAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[5]
Dasotraline	DMLDQFV	Attention deficit hyperactivity disorder	6A05.Z	Approved	[23]
Methylphenidate	DM7SJD6	Attention deficit hyperactivity disorder	6A05.Z	Approved	[24]
Modafinil	DMYILBE	Malignant glioma	2A00.0	Approved	[10]
Phenmetrazine	DMXYTN9	Obesity	5B81	Approved	[25]
Ioflupane i-123	DMNARJT	Parkinson disease	8A00.0	Approved	[14]
DEXMETHYLPHENIDATE HYDROCHLORIDE	DM8WBAH	Attention deficit hyperactivity disorder	6A05.Z	Approved	[26]
Altropane	DMO9WDS	Attention deficit hyperactivity disorder	6A05.Z	Approved	[27]
Amitifadine	DMS1X67	Obesity	5B81	Phase 3	[28]
NAV5001	DMRSI1M	Dementia	6D80-6D86	Phase 3	[27]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine transporter (DAT)	TTVBI8W	SC6A3_HUMAN	Inhibitor	[1]
Muscarinic acetylcholine receptor M1 (CHRM1)	TTZ9SOR	ACM1_HUMAN	Inhibitor	[1]
Norepinephrine transporter (NET)	TTAWNKZ	SC6A2_HUMAN	Inhibitor	[1]
Serotonin transporter (SERT)	TT3ROYC	SC6A4_HUMAN	Inhibitor	[1]

References

• [1] Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogue... J Med Chem. 2006 Oct 19;49(21):6391-9.
• [2] Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
• [3] Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
• [4] Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
• [5] Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
• [6] Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
• [7] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [8] Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
• [9] Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
• [10] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [11] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [12] Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
• [13] Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [15] Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64.
• [16] Accidental acute clidinium toxicity. Emerg Med J. 2009 Jun;26(6):460.
• [17] The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic dr... Psychopharmacology (Berl). 2009 Apr;203(2):295-301.
• [18] Ultraviolet spectroscopic estimation of microenvironments and bitter tastes of oxyphenonium bromide in cyclodextrin solutions. J Pharm Sci. 1999 Aug;88(8):759-62.
• [19] Formulation and biopharmaceutical evaluation of transdermal patch containing benztropine. Int J Pharm. 2008 Jun 5;357(1-2):55-60.
• [20] Autonomic cardiovascular control during a novel pharmacologic alternative to ganglionic blockade. Clin Pharmacol Ther. 2008 May;83(5):692-701.
• [21] Negative crosstalk between M1 and M2 muscarinic autoreceptors involves endogenous adenosine activating A1 receptors at the rat motor endplate. Neurosci Lett. 2009 Aug 14;459(3):127-31.
• [22] Capillary gas chromatography of trihexyphenidyl, procyclidine and cycrimine in biological fluids. J Chromatogr. 1989 Sep 29;494:135-42.
• [23] Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
• [24] Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1410-5.
• [25] Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7.
• [26] Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
• [27] Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun;29(2):128-41.
• [28] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 927).